Phase

Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

by
Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial had two parts: … Read more

Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with … Read more

Zacks Small Cap Research – MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… – Go Health Pro

by

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Encouraging Interim Results from Phase 2b/3 COMBAT-ALS Trial On December 5, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a poster presentation at the 35th International Symposium on ALS/MND would feature a study update and interim analysis results from the ongoing Phase 2b/3 COMBAT-ALS trial … Read more

Zacks Small Cap Research – LEXX: Phase I Start Imminent – Go Health Pro

by
Zacks Small Cap Research – LEXX: Phase I Start Imminent – Go Health Pro

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal third 2024 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase Ib trial evaluating DehydraTECH in obese patients. Several new patents were granted bringing the total to 43. … Read more

Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

by
Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Planning Phase 3 Oral Insulin study under revised protocol, new CRO agreement in place Oramed Pharmaceuticals (NASDAQ:ORMP) has pivoted its clinical R&D focus to prioritize studying ORMD 0801 for subpopulations of patients with pooled specific parameters who responded well to oral insulin in its prior … Read more

x